董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William H. Dunn | 男 | Director | 55 | 17.06万美元 | 3.50 | 2025-12-31 |
| Helen S. Kim | 女 | Independent Director | 62 | 未披露 | 未持股 | 2025-12-31 |
| Daniel G. Welch | 男 | Chairman of the Board | 67 | 19.29万美元 | 6.78 | 2025-12-31 |
| Helen S. Kim | 女 | Independent Director | 62 | 16.08万美元 | 6.00 | 2025-12-31 |
| Lars G. Ekman | 男 | Director | 76 | 17.58万美元 | 12.20 | 2025-12-31 |
| Shane Cooke | 男 | Independent Director | 64 | 18.33万美元 | 12.17 | 2025-12-31 |
| Richard T. Collier | 男 | Independent Director | 72 | 17.58万美元 | 12.30 | 2025-12-31 |
| Gene Kinney | 男 | Director, President and Chief Executive Officer | 56 | 589.60万美元 | 240.01 | 2025-12-31 |
| Dennis J. Selkoe | 男 | Independent Director | 82 | 17.23万美元 | 9.44 | 2025-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Tran B. Nguyen | 男 | Chief Strategy Officer and Chief Financial Officer | 52 | 266.11万美元 | 92.76 | 2025-12-31 |
| Wagner M. Zago | 男 | Chief Scientific Officer | 53 | 241.17万美元 | 59.62 | 2025-12-31 |
| Michael J. Malecek | 男 | Chief Legal Officer and Company Secretary | 60 | 228.90万美元 | 未持股 | 2025-12-31 |
| Brandon S. Smith | 男 | Chief Operating Officer | 51 | 281.20万美元 | 62.68 | 2025-12-31 |
| Chad J. Swanson | 男 | Chief Development Officer | 53 | 241.52万美元 | 21.36 | 2025-12-31 |
| Gene Kinney | 男 | Director, President and Chief Executive Officer | 56 | 589.60万美元 | 240.01 | 2025-12-31 |
| Karin L. Walker | 女 | Chief Accounting Officer | 62 | 未披露 | 未持股 | 2025-12-31 |
董事简历
中英对照 | 中文 | 英文- William H. Dunn
-
William H. Dunn是美国食品和药物管理局神经科学办公室、药物评估和研究中心的创始主任，自2019年该办公室成立至2023年2月，他一直担任该职位。他负责为支持神经科学药物开发而进行的所有研究的监管监督，包括对研究性新药申请以及药物和生物产品的上市申请的监管和审查。2005年至2019年，他在药物评价和研究中心神经病学产品分部担任资历不断增加的职位，包括担任该分部的主任。Dunn博士是一位训练有素的神经科医生和血管神经科医生，在基础研究、临床研究和临床护理方面拥有丰富的经验。他在弗吉尼亚大学获得学士学位，在马里兰州贝塞斯达的F. Edward H é bert医学院获得医学博士学位。自2023年起在Prothena Corporation plc董事会任职。
William H. Dunn,was the founding director of the Office of Neuroscience, Center for Drug Evaluation and Research, at the U.S. Food and Drug Administration, a position he held since the founding of the office in 2019 through February 2023. He was responsible for the regulatory oversight of all research conducted to support neuroscience drug development, including the regulation and review of investigational new drug applications and marketing applications for drug and biologic products. From 2005 to 2019, he held positions of increasing seniority in the Division of Neurology Products, Center for Drug Evaluation and Research, including his role as director of that division. Dr. Dunn is a trained neurologist and vascular neurologist with experience in basic research, clinical research, and clinical care. He earned his B.A. from the University of Virginia and his M.D. from the F. Edward Hébert School of Medicine in Bethesda, Maryland. He has served on Prothena Corporation Plc Board since 2023. - William H. Dunn是美国食品和药物管理局神经科学办公室、药物评估和研究中心的创始主任，自2019年该办公室成立至2023年2月，他一直担任该职位。他负责为支持神经科学药物开发而进行的所有研究的监管监督，包括对研究性新药申请以及药物和生物产品的上市申请的监管和审查。2005年至2019年，他在药物评价和研究中心神经病学产品分部担任资历不断增加的职位，包括担任该分部的主任。Dunn博士是一位训练有素的神经科医生和血管神经科医生，在基础研究、临床研究和临床护理方面拥有丰富的经验。他在弗吉尼亚大学获得学士学位，在马里兰州贝塞斯达的F. Edward H é bert医学院获得医学博士学位。自2023年起在Prothena Corporation plc董事会任职。
- William H. Dunn,was the founding director of the Office of Neuroscience, Center for Drug Evaluation and Research, at the U.S. Food and Drug Administration, a position he held since the founding of the office in 2019 through February 2023. He was responsible for the regulatory oversight of all research conducted to support neuroscience drug development, including the regulation and review of investigational new drug applications and marketing applications for drug and biologic products. From 2005 to 2019, he held positions of increasing seniority in the Division of Neurology Products, Center for Drug Evaluation and Research, including his role as director of that division. Dr. Dunn is a trained neurologist and vascular neurologist with experience in basic research, clinical research, and clinical care. He earned his B.A. from the University of Virginia and his M.D. from the F. Edward Hébert School of Medicine in Bethesda, Maryland. He has served on Prothena Corporation Plc Board since 2023.
- Helen S. Kim
-
Helen S. Kim是Vida Ventures，LLC（一家风险投资公司）的高级董事总经理，她自2019年4月起担任该职位。在担任现职之前，Kim女士于2018年至2019年担任The Column Group（一家风险投资公司）的合伙人，并于2014年至2018年（通过被吉利德科学公司收购）担任Kite Pharma, Inc.（一家专门从事癌症免疫治疗的生物技术公司）业务发展执行副总裁。在此之前，Kim女士曾担任NGM生物制药公司的首席商务官（2009-2012年）和战略顾问（2012-2014年）等职位。在加入NGM之前，她是Kosan Biosciences（一家制药公司）的首席执行官兼总裁，在2008年与百时美施贵宝成功交易之前，她在该公司进行了重组和重新定位。Kim女士的额外行业经验包括在Affymax, Inc.、奥尼斯医药、Protein Design Labs，Inc.（一家技术公司）和Chiron Corporation担任行政和领导职务。Kim女士目前还担任多家私营公司的董事：ReCode Therapeutics，Inc.、IconOVir Bio，Inc.、Aktis Oncology、Protego Therapeutics、Souffle、Alterome、Scorpion Therapeutics和Affinit Therapeutics。Kim女士获得了西北大学化学工程学士学位和芝加哥大学工商管理硕士学位。她自2022年起在Prothena Corporation plc董事会任职。
Helen S. Kim,is a Senior Managing Director at Vida Ventures, LLC (a venture capital firm), a position she has held since April 2019. Prior to her current role, Ms. Kim was a Partner at The Column Group (a venture capital firm) from 2018 to 2019 and the Executive Vice President, Business Development, at Kite Pharma, Inc. (a biotechnology company specializing in cancer immunotherapy) from 2014 to 2018 (through its acquisition by Gilead Sciences, Inc.). Previously, Ms. Kim held positions as Chief Business Officer (2009-2012) and then Strategic Advisor (2012-2014) of NGM Biopharmaceuticals, Inc. Prior to NGM, she was the Chief Executive Officer and President of Kosan Biosciences (a pharmaceutical company) where she restructured and repositioned the company prior to a successful transaction with Bristol Myers Squibb in 2008. Ms. Kim's additional industry experience includes executive and leadership positions at Affymax, Inc., Onyx Pharmaceuticals, Inc., Protein Design Labs, Inc. (a technology company), and Chiron Corporation. Ms. Kim also currently serves as a director of several private companies: ReCode Therapeutics, Inc., IconOVir Bio, Inc., Aktis Oncology, Protego Therapeutics, Souffle, Alterome, Scorpion Therapeutics, and AffiniT Therapeutics. Ms. Kim received a B.S. in Chemical Engineering from Northwestern University and an M.B.A. from the University of Chicago. She has served on Prothena Corporation Plc Board since 2022. - Helen S. Kim是Vida Ventures，LLC（一家风险投资公司）的高级董事总经理，她自2019年4月起担任该职位。在担任现职之前，Kim女士于2018年至2019年担任The Column Group（一家风险投资公司）的合伙人，并于2014年至2018年（通过被吉利德科学公司收购）担任Kite Pharma, Inc.（一家专门从事癌症免疫治疗的生物技术公司）业务发展执行副总裁。在此之前，Kim女士曾担任NGM生物制药公司的首席商务官（2009-2012年）和战略顾问（2012-2014年）等职位。在加入NGM之前，她是Kosan Biosciences（一家制药公司）的首席执行官兼总裁，在2008年与百时美施贵宝成功交易之前，她在该公司进行了重组和重新定位。Kim女士的额外行业经验包括在Affymax, Inc.、奥尼斯医药、Protein Design Labs，Inc.（一家技术公司）和Chiron Corporation担任行政和领导职务。Kim女士目前还担任多家私营公司的董事：ReCode Therapeutics，Inc.、IconOVir Bio，Inc.、Aktis Oncology、Protego Therapeutics、Souffle、Alterome、Scorpion Therapeutics和Affinit Therapeutics。Kim女士获得了西北大学化学工程学士学位和芝加哥大学工商管理硕士学位。她自2022年起在Prothena Corporation plc董事会任职。
- Helen S. Kim,is a Senior Managing Director at Vida Ventures, LLC (a venture capital firm), a position she has held since April 2019. Prior to her current role, Ms. Kim was a Partner at The Column Group (a venture capital firm) from 2018 to 2019 and the Executive Vice President, Business Development, at Kite Pharma, Inc. (a biotechnology company specializing in cancer immunotherapy) from 2014 to 2018 (through its acquisition by Gilead Sciences, Inc.). Previously, Ms. Kim held positions as Chief Business Officer (2009-2012) and then Strategic Advisor (2012-2014) of NGM Biopharmaceuticals, Inc. Prior to NGM, she was the Chief Executive Officer and President of Kosan Biosciences (a pharmaceutical company) where she restructured and repositioned the company prior to a successful transaction with Bristol Myers Squibb in 2008. Ms. Kim's additional industry experience includes executive and leadership positions at Affymax, Inc., Onyx Pharmaceuticals, Inc., Protein Design Labs, Inc. (a technology company), and Chiron Corporation. Ms. Kim also currently serves as a director of several private companies: ReCode Therapeutics, Inc., IconOVir Bio, Inc., Aktis Oncology, Protego Therapeutics, Souffle, Alterome, Scorpion Therapeutics, and AffiniT Therapeutics. Ms. Kim received a B.S. in Chemical Engineering from Northwestern University and an M.B.A. from the University of Chicago. She has served on Prothena Corporation Plc Board since 2022.
- Daniel G. Welch
-
Daniel G. Welch，2007年6月起任公司董事。2003年9月起，他是生物科技公司 InterMune, Inc.的首席执行官和总裁。2007年5月，他还担任InterMune的董事会主席。加入InterMune前，2002至2003年他是Triangle Pharmaceuticals 的主席和首席执行官，该公司2003年被Gilead收购。此前的2000至2002年，他是Elan Corporation生物制药部总裁。在Elan任职期间，他负责美国市场商业运营、国际子公司、研发和诊断业务。1987至2000年，他担任Sanofi-Synthelabo（现Sanofi-Aventis）多个高级管理职位，包括国际市场部副总裁、美国业务部首席运营官等。他获有University of Miami学士学位，以及University of North Carolina的工商管理硕士学位。除Seattle Genetics外，他还担任上市生物科技公司InterMune, Hyperion Therapeutics, Inc.和民营生物科技公司Corium International, Inc.的董事。
Daniel G. Welch,Sofinnova Ventures, a venture capital firm,Executive Partner 2015-2018; retired.InterMune, Inc., a publicly-traded biotechnology company,Chief Executive Officer and President (2003-2014),Chairman of the Board (2007-2014).Intercept Pharmaceuticals, Inc.,Ultragenyx Pharmaceuticals, Inc. (Chairman of the Board),Hyperion Therapeutics, Avexis, Inc.. - Daniel G. Welch，2007年6月起任公司董事。2003年9月起，他是生物科技公司 InterMune, Inc.的首席执行官和总裁。2007年5月，他还担任InterMune的董事会主席。加入InterMune前，2002至2003年他是Triangle Pharmaceuticals 的主席和首席执行官，该公司2003年被Gilead收购。此前的2000至2002年，他是Elan Corporation生物制药部总裁。在Elan任职期间，他负责美国市场商业运营、国际子公司、研发和诊断业务。1987至2000年，他担任Sanofi-Synthelabo（现Sanofi-Aventis）多个高级管理职位，包括国际市场部副总裁、美国业务部首席运营官等。他获有University of Miami学士学位，以及University of North Carolina的工商管理硕士学位。除Seattle Genetics外，他还担任上市生物科技公司InterMune, Hyperion Therapeutics, Inc.和民营生物科技公司Corium International, Inc.的董事。
- Daniel G. Welch,Sofinnova Ventures, a venture capital firm,Executive Partner 2015-2018; retired.InterMune, Inc., a publicly-traded biotechnology company,Chief Executive Officer and President (2003-2014),Chairman of the Board (2007-2014).Intercept Pharmaceuticals, Inc.,Ultragenyx Pharmaceuticals, Inc. (Chairman of the Board),Hyperion Therapeutics, Avexis, Inc..
- Helen S. Kim
-
Helen S. Kim，她目前担任NGM Biopharmaceuticals, Inc.的战略顾问。从2009年8月到2012年1月，她担任其首席商务官。在加入NGM之前的2008年12月到2009年6月，她曾是TRF Pharma的首席执行官。在TRF Pharma任职之前的2008年1月至2008年7月，她担任 Kosan Biosciences, Inc.的总裁和首席执行官。从2003年8月到2007年12月，她担任the Gordon and Betty Moore Foundation的项目总监。从2002年到2003年，她担任Affymax, Inc.的首席商务官。在Affymax任职之前的1999年到2002年，她曾是Onyx Pharmaceuticals, Inc.的高级副总裁负责公司发展。从1989年到1998年，她担任Chiron Corporation的总裁负责战略市场营销。她目前在Immunocellular Therapeutics, Ltd.（一个上市的生物科技公司）、 West Coast Clinical Trial Global（私人全球合同制研究组织）和ForSight VISION4 Inc.（私人眼科保健设备公司）的董事会任职。她获得美国西北大学（ Northwestern University）化学工程学士学位和芝加哥大学（University of Chicago）的工商管理硕士学位。
Helen S. Kim has served as a member of Aktis Oncology, Inc.'s board of directors since February 2021. Since April 2019, Ms. Kim has been a Senior Managing Director of Vida Ventures, LLC, a venture capital firm. From March 2018 to March 2019, Ms. Kim was a Partner at The Column Group, a venture capital firm. Previously, Ms. Kim was the Executive Vice President, Business Development at Kite Pharma, Inc. from June 2014 to January 2018, where she led the business and corporate development initiatives resulting in its acquisition by Gilead in 2017. From August 2009 to November 2014, Ms. Kim worked at NGM Biopharmaceuticals Inc., a biopharmaceutical company, serving in the role of Chief Business Officer from August 2009 to July 2012 and Strategic Advisor from July 2012 to November 2014. From 2007 to 2008, she served as the Chief Executive Officer and President of Kosan Biosciences Inc., a pharmaceutical company, prior to the sale of the company to Bristol Myers Squibb. Prior to this, Ms. Kim held various executive and leadership positions at Affymax, Inc., a biopharmaceutical company, Onyx Pharmaceuticals, Inc., a biopharmaceutical company and subsidiary of Amgen Inc., Protein Design Labs, Inc., a technology company, and Chiron Corporation, a biotechnology company and a subsidiary of Novartis AG. From August 2003 to November 2007, Ms. Kim also served as Chief Program Officer for the Gordon and Betty Moore Foundation, a nonprofit organization. Ms. Kim currently serves on the board of directors of Phylaxis Bioscience, LLC, since September 2024, Prothena Corporation plc (Nasdaq: PRTA), since August 2022, and on the board of directors of the privately held companies, InduPro Labs, since February 2022, Protego Biopharma, since October 2021, IconOVir Bio, Inc., since December 2020, ReCode Therapeutics, Inc., since March 2020, and A2 Biotherapeutics, Inc., since April 2019. Ms. Kim previously served on the board of directors of Applied Molecular Transport, Inc., from October 2018 until April 2022. Ms. Kim received a BS in Chemical Engineering from Northwestern University and an MBA from the University of Chicago. - Helen S. Kim，她目前担任NGM Biopharmaceuticals, Inc.的战略顾问。从2009年8月到2012年1月，她担任其首席商务官。在加入NGM之前的2008年12月到2009年6月，她曾是TRF Pharma的首席执行官。在TRF Pharma任职之前的2008年1月至2008年7月，她担任 Kosan Biosciences, Inc.的总裁和首席执行官。从2003年8月到2007年12月，她担任the Gordon and Betty Moore Foundation的项目总监。从2002年到2003年，她担任Affymax, Inc.的首席商务官。在Affymax任职之前的1999年到2002年，她曾是Onyx Pharmaceuticals, Inc.的高级副总裁负责公司发展。从1989年到1998年，她担任Chiron Corporation的总裁负责战略市场营销。她目前在Immunocellular Therapeutics, Ltd.（一个上市的生物科技公司）、 West Coast Clinical Trial Global（私人全球合同制研究组织）和ForSight VISION4 Inc.（私人眼科保健设备公司）的董事会任职。她获得美国西北大学（ Northwestern University）化学工程学士学位和芝加哥大学（University of Chicago）的工商管理硕士学位。
- Helen S. Kim has served as a member of Aktis Oncology, Inc.'s board of directors since February 2021. Since April 2019, Ms. Kim has been a Senior Managing Director of Vida Ventures, LLC, a venture capital firm. From March 2018 to March 2019, Ms. Kim was a Partner at The Column Group, a venture capital firm. Previously, Ms. Kim was the Executive Vice President, Business Development at Kite Pharma, Inc. from June 2014 to January 2018, where she led the business and corporate development initiatives resulting in its acquisition by Gilead in 2017. From August 2009 to November 2014, Ms. Kim worked at NGM Biopharmaceuticals Inc., a biopharmaceutical company, serving in the role of Chief Business Officer from August 2009 to July 2012 and Strategic Advisor from July 2012 to November 2014. From 2007 to 2008, she served as the Chief Executive Officer and President of Kosan Biosciences Inc., a pharmaceutical company, prior to the sale of the company to Bristol Myers Squibb. Prior to this, Ms. Kim held various executive and leadership positions at Affymax, Inc., a biopharmaceutical company, Onyx Pharmaceuticals, Inc., a biopharmaceutical company and subsidiary of Amgen Inc., Protein Design Labs, Inc., a technology company, and Chiron Corporation, a biotechnology company and a subsidiary of Novartis AG. From August 2003 to November 2007, Ms. Kim also served as Chief Program Officer for the Gordon and Betty Moore Foundation, a nonprofit organization. Ms. Kim currently serves on the board of directors of Phylaxis Bioscience, LLC, since September 2024, Prothena Corporation plc (Nasdaq: PRTA), since August 2022, and on the board of directors of the privately held companies, InduPro Labs, since February 2022, Protego Biopharma, since October 2021, IconOVir Bio, Inc., since December 2020, ReCode Therapeutics, Inc., since March 2020, and A2 Biotherapeutics, Inc., since April 2019. Ms. Kim previously served on the board of directors of Applied Molecular Transport, Inc., from October 2018 until April 2022. Ms. Kim received a BS in Chemical Engineering from Northwestern University and an MBA from the University of Chicago.
- Lars G. Ekman
-
Lars G. Ekman，自2012年起担任Prothena Corporation plc董事会主席。他是Sofinnova Ventures, Inc.（风险投资公司）的执行合伙人，自2008年起担任该职位。他也是Sophiris Bio Inc.的董事会主席，Amarin Corporation plc的董事会主席，以及Ultragenyx Pharmaceutical Inc.（所有这些都是生物技术/生物制药公司）的董事。2009年至2015年，他还担任Ocera Therapeutics, Inc.（一家生物制药公司）的董事；2014年至2019年，担任Spark Therapeutics, Inc.（一家生物制药公司）的董事。他是Cebix Incorporated的联合创始人，从2009年到2012年担任首席执行官。他曾担任Elan Corporation, plc的研发总裁（从2001年到2007年），在那里他还担任董事（从2005年到2012年）。从1997年到2001年，Ekman博士担任Schwarz Pharma AG的执行副总裁，负责研发。在此之前，他曾在Pharmacia Corporation担任多个高级职位。Ekman博士是一名获得委员会认证的外科医生，拥有实验生物学博士学位，并在美国和欧洲担任过多个临床和学术职位。他在瑞典哥德堡大学获得博士和医学博士学位。他自2012年起担任Prothena Corporation plc董事会成员。
Lars G. Ekman, is Chairman of Prothena Corporation plc Board of Directors, a position he has held since 2012. He is an executive partner at Sofinnova Ventures, Inc. a venture capital firm, a position he has held since 2008. Dr. Ekman is also Chairman of the Board of Sophiris Bio Inc., Chairman of the Board of Amarin Corporation plc, and a director of Ultragenyx Pharmaceutical Inc. (all of which are biotechnology/biopharmaceutical companies). He also served as a director of Ocera Therapeutics, Inc. (a biopharmaceutical company) from 2009 to 2015 and as a director of Spark Therapeutics, Inc. (a biopharmaceutical company) from 2014 to 2019. Dr. Ekman co-founded Cebix Incorporated, where he served as Chief Executive Officer from 2009 to 2012. He was President of Research & Development at Elan Corporation, plc (from 2001 to 2007), where he also served as a director (from 2005 to 2012). From 1997 to 2001 Dr. Ekman was Executive Vice President, Research & Development at Schwarz Pharma AG. Prior to that, he held various senior positions at Pharmacia Corporation. Dr. Ekman is a board-certified surgeon with a Ph.D. in experimental biology and has held several clinical and academic positions in both the United States and Europe. He earned his Ph.D. and M.D. from the University of Gothenburg, Sweden. Dr. Ekman has served on Prothena Corporation plc Board since 2012. - Lars G. Ekman，自2012年起担任Prothena Corporation plc董事会主席。他是Sofinnova Ventures, Inc.（风险投资公司）的执行合伙人，自2008年起担任该职位。他也是Sophiris Bio Inc.的董事会主席，Amarin Corporation plc的董事会主席，以及Ultragenyx Pharmaceutical Inc.（所有这些都是生物技术/生物制药公司）的董事。2009年至2015年，他还担任Ocera Therapeutics, Inc.（一家生物制药公司）的董事；2014年至2019年，担任Spark Therapeutics, Inc.（一家生物制药公司）的董事。他是Cebix Incorporated的联合创始人，从2009年到2012年担任首席执行官。他曾担任Elan Corporation, plc的研发总裁（从2001年到2007年），在那里他还担任董事（从2005年到2012年）。从1997年到2001年，Ekman博士担任Schwarz Pharma AG的执行副总裁，负责研发。在此之前，他曾在Pharmacia Corporation担任多个高级职位。Ekman博士是一名获得委员会认证的外科医生，拥有实验生物学博士学位，并在美国和欧洲担任过多个临床和学术职位。他在瑞典哥德堡大学获得博士和医学博士学位。他自2012年起担任Prothena Corporation plc董事会成员。
- Lars G. Ekman, is Chairman of Prothena Corporation plc Board of Directors, a position he has held since 2012. He is an executive partner at Sofinnova Ventures, Inc. a venture capital firm, a position he has held since 2008. Dr. Ekman is also Chairman of the Board of Sophiris Bio Inc., Chairman of the Board of Amarin Corporation plc, and a director of Ultragenyx Pharmaceutical Inc. (all of which are biotechnology/biopharmaceutical companies). He also served as a director of Ocera Therapeutics, Inc. (a biopharmaceutical company) from 2009 to 2015 and as a director of Spark Therapeutics, Inc. (a biopharmaceutical company) from 2014 to 2019. Dr. Ekman co-founded Cebix Incorporated, where he served as Chief Executive Officer from 2009 to 2012. He was President of Research & Development at Elan Corporation, plc (from 2001 to 2007), where he also served as a director (from 2005 to 2012). From 1997 to 2001 Dr. Ekman was Executive Vice President, Research & Development at Schwarz Pharma AG. Prior to that, he held various senior positions at Pharmacia Corporation. Dr. Ekman is a board-certified surgeon with a Ph.D. in experimental biology and has held several clinical and academic positions in both the United States and Europe. He earned his Ph.D. and M.D. from the University of Gothenburg, Sweden. Dr. Ekman has served on Prothena Corporation plc Board since 2012.
- Shane Cooke
-
Shane Cooke，自2011年9月他担任公司总裁。他受雇于Alkermes 爱尔兰制药有限公司（公司的爱尔兰子公司）。从2005年5月至2011年9月16日他担任Elan公司的董事。从2007年5月至2011 年9月16日他曾任Elan公司的执行副总裁和EDT的负责人。从2001年7月加入义隆直到2011年5月，他曾任义隆电子的财务总监。在加入义隆前，他曾任彭布罗克资本有限公司（航空租赁公司）的首席执行官，而在此之前，在一些银行和航空业担任金融高级职位。他是一名注册会计师。他目前是Prothena公司（一家公开上市的生物技术公司）和Onclave（一家私人持有的公司）的董事。
Shane Cooke,served as President and as President of Alkermes Pharma Ireland Limited ("APIL"), a wholly-owned subsidiary of the Company, from September 2011 until his retirement in March 2018. He became a member of Board upon his retirement. In addition, Mr. Cooke has been chairman of the board of directors of APIL since September 2011. Mr. Cooke served as Executive Vice President of Elan Corporation, plc ("Elan") and Head of Elan Drug Technologies from May 2007 to September 16, 2011 and as the Chief Financial Officer of Elan from July 2001 until May 2011. Mr. Cooke served as a director of Elan from May 2005 to September 16, 2011. Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company, and prior to that, he held a number of senior finance positions in the banking and aviation industries. Mr. Cooke previously served on the board of directors of then publicly-traded healthcare companies UDG Healthcare plc from February 2019 to August 2021 and Endo International plc from July 2014 to April 2024. He is a chartered accountant. - Shane Cooke，自2011年9月他担任公司总裁。他受雇于Alkermes 爱尔兰制药有限公司（公司的爱尔兰子公司）。从2005年5月至2011年9月16日他担任Elan公司的董事。从2007年5月至2011 年9月16日他曾任Elan公司的执行副总裁和EDT的负责人。从2001年7月加入义隆直到2011年5月，他曾任义隆电子的财务总监。在加入义隆前，他曾任彭布罗克资本有限公司（航空租赁公司）的首席执行官，而在此之前，在一些银行和航空业担任金融高级职位。他是一名注册会计师。他目前是Prothena公司（一家公开上市的生物技术公司）和Onclave（一家私人持有的公司）的董事。
- Shane Cooke,served as President and as President of Alkermes Pharma Ireland Limited ("APIL"), a wholly-owned subsidiary of the Company, from September 2011 until his retirement in March 2018. He became a member of Board upon his retirement. In addition, Mr. Cooke has been chairman of the board of directors of APIL since September 2011. Mr. Cooke served as Executive Vice President of Elan Corporation, plc ("Elan") and Head of Elan Drug Technologies from May 2007 to September 16, 2011 and as the Chief Financial Officer of Elan from July 2001 until May 2011. Mr. Cooke served as a director of Elan from May 2005 to September 16, 2011. Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company, and prior to that, he held a number of senior finance positions in the banking and aviation industries. Mr. Cooke previously served on the board of directors of then publicly-traded healthcare companies UDG Healthcare plc from February 2019 to August 2021 and Endo International plc from July 2014 to April 2024. He is a chartered accountant.
- Richard T. Collier
-
Richard T. Collier，自2012年12月起担任Prothena的董事。Collier先生目前是费城The Temple University Beasley School of Law的法学客座教授，自2004年起教授药品和医疗设备法律。他有着近25年的全球制药和生物技术行业执行职位的经验。Collier先生另外也担任了三家上市的全球制药公司的高级副总裁和总顾问：Rhone-Poulenc Rorer Inc.； Pharmacia & Upjohn Company； 和Pharmacia Corporation。 最近，Collier先生担任了Elan的执行副总裁和总顾问。在他的从商早期，Collier先生在两家领先的总部在费城的法律事务所的私人律师，也在华盛顿的the U.S. Federal Trade Commission和费城的the U.S. Department of Justice任职。Collier先生获得了Temple University的学士和法学博士学位。
Richard T. Collier is the former Executive Vice President and General Counsel of Elan Corporation, plc a pharmaceutical company, a position he held from 2004 to 2010. Prior to that, he served as Senior Vice President and General Counsel of Rhone-Poulenc Rorer Inc., Pharmacia & Upjohn Company and Pharmacia Corporation (all pharmaceutical companies). Mr. Collier was an Adjunct Professor of Law at the Temple University Beasley School of Law, where he taught drug and medical device law, from 2004 to 2017. He also practiced law at two leading Philadelphia-based law firms and with the U.S. Federal Trade Commission and U.S. Department of Justice. Mr. Collier earned both his B.A. and his J.D. (law degree) from Temple University. He has served on Board since 2012. - Richard T. Collier，自2012年12月起担任Prothena的董事。Collier先生目前是费城The Temple University Beasley School of Law的法学客座教授，自2004年起教授药品和医疗设备法律。他有着近25年的全球制药和生物技术行业执行职位的经验。Collier先生另外也担任了三家上市的全球制药公司的高级副总裁和总顾问：Rhone-Poulenc Rorer Inc.； Pharmacia & Upjohn Company； 和Pharmacia Corporation。 最近，Collier先生担任了Elan的执行副总裁和总顾问。在他的从商早期，Collier先生在两家领先的总部在费城的法律事务所的私人律师，也在华盛顿的the U.S. Federal Trade Commission和费城的the U.S. Department of Justice任职。Collier先生获得了Temple University的学士和法学博士学位。
- Richard T. Collier is the former Executive Vice President and General Counsel of Elan Corporation, plc a pharmaceutical company, a position he held from 2004 to 2010. Prior to that, he served as Senior Vice President and General Counsel of Rhone-Poulenc Rorer Inc., Pharmacia & Upjohn Company and Pharmacia Corporation (all pharmaceutical companies). Mr. Collier was an Adjunct Professor of Law at the Temple University Beasley School of Law, where he taught drug and medical device law, from 2004 to 2017. He also practiced law at two leading Philadelphia-based law firms and with the U.S. Federal Trade Commission and U.S. Department of Justice. Mr. Collier earned both his B.A. and his J.D. (law degree) from Temple University. He has served on Board since 2012.
- Gene Kinney
-
Gene Kinney，自2016年起担任Prothena Corporation plc总裁兼首席执行官。在此之前，他在2016年部分时间担任Prothena Corporation plc首席运营官，在此之前，他在2012年至2016年期间担任Prothena Corporation plc首席科学官和研发主管。2009年至2012年，Kinney博士在Elan Pharmaceuticals，Inc.担任过多个职位：药理学副总裁（2011年至2012年）和药理科学高级副总裁（2009年至2011年）；在这些职位上，他还担任过杨森阿尔茨海默氏症免疫疗法研发的非临床研究主管。从2001年到2009年，Kinney博士在默沙东研究实验室担任高级主任、中央药理学负责人以及生物分析和病理学代理负责人，在那里他为药物发现活动的战略方向和监督做出了贡献，并领导了许多针对神经退行性和精神疾病治疗的非临床发现和临床开发项目。Kinney博士还曾在百时美施贵宝任职，曾任埃默里大学医学院精神病学和行为科学系助理教授。他在布卢姆斯堡大学获得了学士学位，在佛罗里达大西洋大学获得了硕士和博士学位。Kinney博士自2016年起在Prothena Corporation plc董事会任职。
Gene Kinney,as served as Prothena Corporation Plc President and Chief Executive Officer since 2016. Prior to that, he was Prothena Corporation Plc Chief Operating Officer for part of 2016, and prior to that he was Prothena Corporation Plc Chief Scientific Officer and Head of Research and Development from 2012 to 2016. From 2009 to 2012, Dr. Kinney held various positions with Elan Pharmaceuticals, Inc.: Vice President, Pharmacology (from 2011 to 2012) and Senior Vice President of Pharmacological Sciences (from 2009 to 2011); and while in those positions, he also served as Head of Nonclinical Research for Janssen Alzheimer Immunotherapy R&D. From 2001 to 2009, Dr. Kinney was Senior Director, Head of Central Pharmacology and acting lead for Bioanalytics & Pathology at the Merck Research Laboratories, where he contributed to the strategic direction and oversight of drug discovery activities and led a number of non-clinical discovery and clinical development programs targeted for the treatment of neurodegenerative and psychiatric conditions. Dr. Kinney also held positions at Bristol Myers Squibb and was an Assistant Professor at the Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences. He earned his B.A. from Bloomsburg University and his M.A. and Ph.D. from Florida Atlantic University. Dr. Kinney has served on Prothena Corporation Plc Board since 2016. - Gene Kinney，自2016年起担任Prothena Corporation plc总裁兼首席执行官。在此之前，他在2016年部分时间担任Prothena Corporation plc首席运营官，在此之前，他在2012年至2016年期间担任Prothena Corporation plc首席科学官和研发主管。2009年至2012年，Kinney博士在Elan Pharmaceuticals，Inc.担任过多个职位：药理学副总裁（2011年至2012年）和药理科学高级副总裁（2009年至2011年）；在这些职位上，他还担任过杨森阿尔茨海默氏症免疫疗法研发的非临床研究主管。从2001年到2009年，Kinney博士在默沙东研究实验室担任高级主任、中央药理学负责人以及生物分析和病理学代理负责人，在那里他为药物发现活动的战略方向和监督做出了贡献，并领导了许多针对神经退行性和精神疾病治疗的非临床发现和临床开发项目。Kinney博士还曾在百时美施贵宝任职，曾任埃默里大学医学院精神病学和行为科学系助理教授。他在布卢姆斯堡大学获得了学士学位，在佛罗里达大西洋大学获得了硕士和博士学位。Kinney博士自2016年起在Prothena Corporation plc董事会任职。
- Gene Kinney,as served as Prothena Corporation Plc President and Chief Executive Officer since 2016. Prior to that, he was Prothena Corporation Plc Chief Operating Officer for part of 2016, and prior to that he was Prothena Corporation Plc Chief Scientific Officer and Head of Research and Development from 2012 to 2016. From 2009 to 2012, Dr. Kinney held various positions with Elan Pharmaceuticals, Inc.: Vice President, Pharmacology (from 2011 to 2012) and Senior Vice President of Pharmacological Sciences (from 2009 to 2011); and while in those positions, he also served as Head of Nonclinical Research for Janssen Alzheimer Immunotherapy R&D. From 2001 to 2009, Dr. Kinney was Senior Director, Head of Central Pharmacology and acting lead for Bioanalytics & Pathology at the Merck Research Laboratories, where he contributed to the strategic direction and oversight of drug discovery activities and led a number of non-clinical discovery and clinical development programs targeted for the treatment of neurodegenerative and psychiatric conditions. Dr. Kinney also held positions at Bristol Myers Squibb and was an Assistant Professor at the Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences. He earned his B.A. from Bloomsburg University and his M.A. and Ph.D. from Florida Atlantic University. Dr. Kinney has served on Prothena Corporation Plc Board since 2016.
- Dennis J. Selkoe
-
Dennis J. Selkoe，2013年7月以来，担任Prothena董事。目前，Selkoe博士是哈佛医学院（Harvard Medical School）神经疾病Vincent and Stella Coates教授，Brigham和波士顿妇女医院神经疾病中心的主任。Selkoe博士是主创科学家，并且是Athena Neurosciences的董事，直到它在1996年被Elan收购。Selkoe博士以前在Elan董事会的任职，直到2013年5月。Selkoe博士，获得了哥伦比亚大学（Columbia University）历史学士学位，弗吉尼亚大学医学院（university of Virginia School of Medicine）的医学博士学位。
Dennis J. Selkoe, is the Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital in Boston, positions he has held since 2000 and 1985 respectively. He has served on the faculty at Harvard Medical School since 1978. Dr. Selkoe was the principal founding scientist and served as a director of Athena Neurosciences, Inc. until it was acquired by Elan Corporation, plc in 1996. He has received numerous honors, including the Mathilde Solowey Award in the Neurosciences NIH, the Potamkin Prize (American Academy of Neurology), the A.H. Heineken Prize for Medicine (The Netherlands), the Pioneer Award and the Lifetime Achievement Award (Alzheimer's Association), the George C. Cotzias Lecture of the American Academy of Neurology and the Ulysses Medal of University College Dublin. Dr. Selkoe is a Fellow of the American Academy of Neurology, the American Association for the Advancement of Science and the American College of Physicians, an elected member of the National Academy of Medicine and a director of the Foundation for Neurologic Diseases. He served as a director of Elan from 1996 to 2013. Dr. Selkoe earned his B.A. from Columbia University and his M.D. from the University of Virginia. He has served on Board since 2013. - Dennis J. Selkoe，2013年7月以来，担任Prothena董事。目前，Selkoe博士是哈佛医学院（Harvard Medical School）神经疾病Vincent and Stella Coates教授，Brigham和波士顿妇女医院神经疾病中心的主任。Selkoe博士是主创科学家，并且是Athena Neurosciences的董事，直到它在1996年被Elan收购。Selkoe博士以前在Elan董事会的任职，直到2013年5月。Selkoe博士，获得了哥伦比亚大学（Columbia University）历史学士学位，弗吉尼亚大学医学院（university of Virginia School of Medicine）的医学博士学位。
- Dennis J. Selkoe, is the Vincent and Stella Coates Professor of Neurologic Diseases at Harvard Medical School and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital in Boston, positions he has held since 2000 and 1985 respectively. He has served on the faculty at Harvard Medical School since 1978. Dr. Selkoe was the principal founding scientist and served as a director of Athena Neurosciences, Inc. until it was acquired by Elan Corporation, plc in 1996. He has received numerous honors, including the Mathilde Solowey Award in the Neurosciences NIH, the Potamkin Prize (American Academy of Neurology), the A.H. Heineken Prize for Medicine (The Netherlands), the Pioneer Award and the Lifetime Achievement Award (Alzheimer's Association), the George C. Cotzias Lecture of the American Academy of Neurology and the Ulysses Medal of University College Dublin. Dr. Selkoe is a Fellow of the American Academy of Neurology, the American Association for the Advancement of Science and the American College of Physicians, an elected member of the National Academy of Medicine and a director of the Foundation for Neurologic Diseases. He served as a director of Elan from 1996 to 2013. Dr. Selkoe earned his B.A. from Columbia University and his M.D. from the University of Virginia. He has served on Board since 2013.
高管简历
中英对照 | 中文 | 英文- Tran B. Nguyen
Tran B. Nguyen，自2016年3月起担任公司董事会成员。自2013年3月起，Mr. Nguyen担任生物科技公司 Prothena Corporation Plc首席财务官。2010年至2011年， Mr. Nguyen曾在医药公司Somaxon Pharmaceuticals, Inc担任副总裁兼首席财务官，2011年起担任高级副总裁兼首席财务官直至2013年公司被售卖。他还曾担任Metabasis Therapeutics, Inc副总裁，首席财务官兼投资关系顾问，Citi Global Markets Inc医疗健康投资银行副总裁，并在Lehman Brothers, Inc担任投资银行家。 Mr. Nguyen获得了Claremont McKenna College学士学位和洛杉矶University of California安德森管理学院工商管理硕士学位。
Tran B. Nguyen has served as a member of Rain Therapeutics Inc.'s Board since April 2018. Mr. Nguyen has served as Chief Financial Officer of Prothena Corporation PLC, a neuroscience company, since March 2013 and as Chief Operating Officer since June 2018. From April 2010 until its sale to Pernix Therapeutics Holdings, Inc. NYSE: PTX, a pharmaceutical company, in March 2013 Mr. Nguyen was Chief Financial Officer of Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company. From March 2009 until its sale to Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a biopharmaceutical company, in January 2010 he served as Chief Financial Officer of Metabasis Therapeutics, Inc., a biopharmaceutical company. Earlier in his career, Mr. Nguyen was a Vice President in the Healthcare Investment Banking group at Citigroup Global Markets Inc. and served in various capacities as a healthcare investment banker at Lehman Brothers, Inc. Mr. Nguyen earned his B.A. in Economics and Psychology from Claremont McKenna College and his M.B.A. from the Anderson School of Management at the University of California, Los Angeles.- Tran B. Nguyen，自2016年3月起担任公司董事会成员。自2013年3月起，Mr. Nguyen担任生物科技公司 Prothena Corporation Plc首席财务官。2010年至2011年， Mr. Nguyen曾在医药公司Somaxon Pharmaceuticals, Inc担任副总裁兼首席财务官，2011年起担任高级副总裁兼首席财务官直至2013年公司被售卖。他还曾担任Metabasis Therapeutics, Inc副总裁，首席财务官兼投资关系顾问，Citi Global Markets Inc医疗健康投资银行副总裁，并在Lehman Brothers, Inc担任投资银行家。 Mr. Nguyen获得了Claremont McKenna College学士学位和洛杉矶University of California安德森管理学院工商管理硕士学位。
- Tran B. Nguyen has served as a member of Rain Therapeutics Inc.'s Board since April 2018. Mr. Nguyen has served as Chief Financial Officer of Prothena Corporation PLC, a neuroscience company, since March 2013 and as Chief Operating Officer since June 2018. From April 2010 until its sale to Pernix Therapeutics Holdings, Inc. NYSE: PTX, a pharmaceutical company, in March 2013 Mr. Nguyen was Chief Financial Officer of Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company. From March 2009 until its sale to Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a biopharmaceutical company, in January 2010 he served as Chief Financial Officer of Metabasis Therapeutics, Inc., a biopharmaceutical company. Earlier in his career, Mr. Nguyen was a Vice President in the Healthcare Investment Banking group at Citigroup Global Markets Inc. and served in various capacities as a healthcare investment banker at Lehman Brothers, Inc. Mr. Nguyen earned his B.A. in Economics and Psychology from Claremont McKenna College and his M.B.A. from the Anderson School of Management at the University of California, Los Angeles.
- Wagner M. Zago
WagnerM.Zago自2017年以来一直担任我们的首席科学官。在此之前，从2015年到2017年，他是我们的Vice President，研究主管。从2012年到2015年，Zago博士担任我们的药理学和神经病理学主管。从2006年到2012年，他曾担任Elan Pharmaceuticals公司的多种科学职务，从事旨在开发中枢神经系统疾病和炎症的新疗法的研究。在担任这些职位期间，从2009年到2013年，Zago博士还担任Janssen Alzheimer Immunotherapy（一家生物制药公司的强生公司公司）的科学家。他在巴西圣保罗联邦大学（Escola Paulista de Medicina）获得生物医学学士学位，在巴西圣保罗大学（Universidade de Sao Paulo，Brazil）获得医学硕士和博士学位（均为药理学），是加州大学圣地亚哥分校和伯纳姆研究所的博士后研究员。
Wagner M. Zago has served as Chief Scientific Officer since 2017. Prior to that, from 2015 to 2017 he was Vice President, Head of Research. From 2012 to 2015 Dr. Zago was Head of Pharmacology and Neuropathology. From 2006 to 2012 he held various scientific positions at Elan Pharmaceuticals, Inc, performing research aimed at developing new therapeutics for central nervous system disorders and inflammation. While in these positions, from 2009 to 2013 Dr. Zago also served as a scientist at Janssen Alzheimer Immunotherapy, a Johnson & Johnson Company a biopharmaceutical company. He earned his BS in Biomedicine from the Universidade Federal de Sao Paulo (Escola Paulista de Medicina), Brazil, and his MS and PhD (both in Pharmacology) from the Universidade de Sao Paulo, Brazil, and was a Post-Doctoral Researcher at the University of California, San Diego and the Burnham Institute.- WagnerM.Zago自2017年以来一直担任我们的首席科学官。在此之前，从2015年到2017年，他是我们的Vice President，研究主管。从2012年到2015年，Zago博士担任我们的药理学和神经病理学主管。从2006年到2012年，他曾担任Elan Pharmaceuticals公司的多种科学职务，从事旨在开发中枢神经系统疾病和炎症的新疗法的研究。在担任这些职位期间，从2009年到2013年，Zago博士还担任Janssen Alzheimer Immunotherapy（一家生物制药公司的强生公司公司）的科学家。他在巴西圣保罗联邦大学（Escola Paulista de Medicina）获得生物医学学士学位，在巴西圣保罗大学（Universidade de Sao Paulo，Brazil）获得医学硕士和博士学位（均为药理学），是加州大学圣地亚哥分校和伯纳姆研究所的博士后研究员。
- Wagner M. Zago has served as Chief Scientific Officer since 2017. Prior to that, from 2015 to 2017 he was Vice President, Head of Research. From 2012 to 2015 Dr. Zago was Head of Pharmacology and Neuropathology. From 2006 to 2012 he held various scientific positions at Elan Pharmaceuticals, Inc, performing research aimed at developing new therapeutics for central nervous system disorders and inflammation. While in these positions, from 2009 to 2013 Dr. Zago also served as a scientist at Janssen Alzheimer Immunotherapy, a Johnson & Johnson Company a biopharmaceutical company. He earned his BS in Biomedicine from the Universidade Federal de Sao Paulo (Escola Paulista de Medicina), Brazil, and his MS and PhD (both in Pharmacology) from the Universidade de Sao Paulo, Brazil, and was a Post-Doctoral Researcher at the University of California, San Diego and the Burnham Institute.
- Michael J. Malecek
MichaelJ.Malecek自2019年7月起担任我们的首席法务官兼公司秘书。在2019年加入Prothena之前，他从2018年起担任数据仓库公司雪花（Snowflake A）知识产权和诉讼副总法律顾问Vice President。从2010年到2018年，他曾担任Arnold&Porter Kaye Scholer LLP的合伙人。从2008年到2010年，Malecek先生是Dewey&LeBoeuf，LLP的合伙人。从2002年到2008年，他是Affymetrix（一家生物技术公司）的Vice President和首席法律顾问。Malecek先生在耶鲁大学（Yale University）获得美国研究学士学位，并在弗吉尼亚大学法学院（University of Virginia School of Law）获得法学博士学位。
Michael J. Malecek has served as Chief Legal Officer and as Company Secretary since July 2019. Prior to joining Prothena in 2019 he was Vice President, Deputy General Counsel, Intellectual Property and Litigation of Snowflake a data warehouse company from 2018. From 2010 to 2018 he was a Partner at Arnold & Porter Kaye Scholer LLP. From 2008 to 2010 Mr. Malecek was Partner at Dewey & LeBoeuf, LLP. From 2002-2008 he was Vice President and Chief Advocacy Counsel at Affymetrix (a biotechnology company). Mr. Malecek earned his BA in American Studies from Yale University and his JD (law degree) from the University of Virginia School of Law.- MichaelJ.Malecek自2019年7月起担任我们的首席法务官兼公司秘书。在2019年加入Prothena之前，他从2018年起担任数据仓库公司雪花（Snowflake A）知识产权和诉讼副总法律顾问Vice President。从2010年到2018年，他曾担任Arnold&Porter Kaye Scholer LLP的合伙人。从2008年到2010年，Malecek先生是Dewey&LeBoeuf，LLP的合伙人。从2002年到2008年，他是Affymetrix（一家生物技术公司）的Vice President和首席法律顾问。Malecek先生在耶鲁大学（Yale University）获得美国研究学士学位，并在弗吉尼亚大学法学院（University of Virginia School of Law）获得法学博士学位。
- Michael J. Malecek has served as Chief Legal Officer and as Company Secretary since July 2019. Prior to joining Prothena in 2019 he was Vice President, Deputy General Counsel, Intellectual Property and Litigation of Snowflake a data warehouse company from 2018. From 2010 to 2018 he was a Partner at Arnold & Porter Kaye Scholer LLP. From 2008 to 2010 Mr. Malecek was Partner at Dewey & LeBoeuf, LLP. From 2002-2008 he was Vice President and Chief Advocacy Counsel at Affymetrix (a biotechnology company). Mr. Malecek earned his BA in American Studies from Yale University and his JD (law degree) from the University of Virginia School of Law.
- Brandon S. Smith
BrandonS.Smith自2020年以来一直担任我们的首席商务官。在加入Prothena之前，他于2017年至2020年担任生物制药公司Iconic Therapeutics的首席运营官。在Impax Therapeutics之前，史密斯先生曾于2012年至2017年在Impax Laboratories（一家专业制药公司）担任高级职位，包括高级副总裁，和企业发展与战略Vice President。Smith先生还在2005年至2012年期间在Amgen（一家生物制药公司）担任过多个职责递增的职位，包括生物仿制药战略执行总监，战略和企业发展总监以及运营战略总监。Smith先生从2002年到2005年也是波士顿咨询集团（The Boston Consulting Group）（一家管理咨询公司）的顾问和项目负责人。Smith先生在密歇根大学（University of Michigan）获得化学工程学士学位，并在德克萨斯大学奥斯汀麦康姆斯商学院（University of Texas at Austin McCombs Graduate School of Business）获得工商管理硕士学位。
Brandon S. Smith has served as Chief Business Officer since 2020. Prior to joining Prothena, he was Chief Operating Officer at Iconic Therapeutics a biopharmaceutical company from 2017 to 2020. Before Iconic Therapeutics, Mr. Smith held senior positions at Impax Laboratories (a specialty pharmaceutical company) between 2012 and 2017 including Senior Vice President, and Vice President of Corporate Development and Strategy. Mr. Smith also held several positions of increasing responsibility at Amgen (a biopharmaceutical company) between 2005 and 2012 including Executive Director, Biosimilars Strategy, Director, Strategy and Corporate Development and Director Operations Strategy. Mr. Smith was also a Consultant and Project Leader at The Boston Consulting Group (a management consulting firm) between 2002 and 2005. Mr. Smith earned his BA in Chemical Engineering at the University of Michigan and his MBA at The University of Texas at Austin McCombs Graduate School of Business.- BrandonS.Smith自2020年以来一直担任我们的首席商务官。在加入Prothena之前，他于2017年至2020年担任生物制药公司Iconic Therapeutics的首席运营官。在Impax Therapeutics之前，史密斯先生曾于2012年至2017年在Impax Laboratories（一家专业制药公司）担任高级职位，包括高级副总裁，和企业发展与战略Vice President。Smith先生还在2005年至2012年期间在Amgen（一家生物制药公司）担任过多个职责递增的职位，包括生物仿制药战略执行总监，战略和企业发展总监以及运营战略总监。Smith先生从2002年到2005年也是波士顿咨询集团（The Boston Consulting Group）（一家管理咨询公司）的顾问和项目负责人。Smith先生在密歇根大学（University of Michigan）获得化学工程学士学位，并在德克萨斯大学奥斯汀麦康姆斯商学院（University of Texas at Austin McCombs Graduate School of Business）获得工商管理硕士学位。
- Brandon S. Smith has served as Chief Business Officer since 2020. Prior to joining Prothena, he was Chief Operating Officer at Iconic Therapeutics a biopharmaceutical company from 2017 to 2020. Before Iconic Therapeutics, Mr. Smith held senior positions at Impax Laboratories (a specialty pharmaceutical company) between 2012 and 2017 including Senior Vice President, and Vice President of Corporate Development and Strategy. Mr. Smith also held several positions of increasing responsibility at Amgen (a biopharmaceutical company) between 2005 and 2012 including Executive Director, Biosimilars Strategy, Director, Strategy and Corporate Development and Director Operations Strategy. Mr. Smith was also a Consultant and Project Leader at The Boston Consulting Group (a management consulting firm) between 2002 and 2005. Mr. Smith earned his BA in Chemical Engineering at the University of Michigan and his MBA at The University of Texas at Austin McCombs Graduate School of Business.
- Chad J. Swanson
Chad J. Swanson，自2024年9月起担任首席发展官。2023年1月至2024年9月任高级副总裁、临床开发负责人。在加入Prothena之前，他曾于2011年至2022年12月在Eisai，Inc.担任多个职责日益增加的职位，包括担任lecanemab项目的国际项目组组长，领导首个以β淀粉样蛋白为靶点的阿尔茨海默病疗法的临床开发，并获得美国食品药品监督管理局的全面批准。在担任该职务之前，斯旺森博士曾在先灵葆雅和默沙东研究实验室担任临床研究职务，并担任发现研究职务，最终担任Lundbeck Research US，Inc.神经化学美国主管。斯旺森博士在威斯康星大学麦迪逊分校获得学士学位，在南卡罗来纳医科大学获得博士学位，同时在礼来公司完成博士后培训。
Chad J. Swanson,has served as Chief Development Officer since September 2024. He served as SVP, Head of Clinical Development from January 2023 to September 2024. Prior to joining Prothena, he held several positions of increasing responsibility at Eisai, Inc. from 2011 to December 2022, including as the International Project Team Leader for the lecanemab program, leading clinical development for the first Alzheimer's disease therapy targeting amyloid beta to receive full approval from the U.S. Food and Drug Administration. Prior to that role, Dr. Swanson held clinical research roles at Schering Plough and Merck Research Laboratories, and discovery research roles culminating as the US Head of Neurochemistry at Lundbeck Research US, Inc. Dr. Swanson earned his BS from the University of Wisconsin-Madison and his PhD from Medical University of South Carolina, while completing postdoctoral training at Eli Lilly and Co.- Chad J. Swanson，自2024年9月起担任首席发展官。2023年1月至2024年9月任高级副总裁、临床开发负责人。在加入Prothena之前，他曾于2011年至2022年12月在Eisai，Inc.担任多个职责日益增加的职位，包括担任lecanemab项目的国际项目组组长，领导首个以β淀粉样蛋白为靶点的阿尔茨海默病疗法的临床开发，并获得美国食品药品监督管理局的全面批准。在担任该职务之前，斯旺森博士曾在先灵葆雅和默沙东研究实验室担任临床研究职务，并担任发现研究职务，最终担任Lundbeck Research US，Inc.神经化学美国主管。斯旺森博士在威斯康星大学麦迪逊分校获得学士学位，在南卡罗来纳医科大学获得博士学位，同时在礼来公司完成博士后培训。
- Chad J. Swanson,has served as Chief Development Officer since September 2024. He served as SVP, Head of Clinical Development from January 2023 to September 2024. Prior to joining Prothena, he held several positions of increasing responsibility at Eisai, Inc. from 2011 to December 2022, including as the International Project Team Leader for the lecanemab program, leading clinical development for the first Alzheimer's disease therapy targeting amyloid beta to receive full approval from the U.S. Food and Drug Administration. Prior to that role, Dr. Swanson held clinical research roles at Schering Plough and Merck Research Laboratories, and discovery research roles culminating as the US Head of Neurochemistry at Lundbeck Research US, Inc. Dr. Swanson earned his BS from the University of Wisconsin-Madison and his PhD from Medical University of South Carolina, while completing postdoctoral training at Eli Lilly and Co.
- Gene Kinney
Gene Kinney，自2016年起担任Prothena Corporation plc总裁兼首席执行官。在此之前，他在2016年部分时间担任Prothena Corporation plc首席运营官，在此之前，他在2012年至2016年期间担任Prothena Corporation plc首席科学官和研发主管。2009年至2012年，Kinney博士在Elan Pharmaceuticals，Inc.担任过多个职位：药理学副总裁（2011年至2012年）和药理科学高级副总裁（2009年至2011年）；在这些职位上，他还担任过杨森阿尔茨海默氏症免疫疗法研发的非临床研究主管。从2001年到2009年，Kinney博士在默沙东研究实验室担任高级主任、中央药理学负责人以及生物分析和病理学代理负责人，在那里他为药物发现活动的战略方向和监督做出了贡献，并领导了许多针对神经退行性和精神疾病治疗的非临床发现和临床开发项目。Kinney博士还曾在百时美施贵宝任职，曾任埃默里大学医学院精神病学和行为科学系助理教授。他在布卢姆斯堡大学获得了学士学位，在佛罗里达大西洋大学获得了硕士和博士学位。Kinney博士自2016年起在Prothena Corporation plc董事会任职。
Gene Kinney,as served as Prothena Corporation Plc President and Chief Executive Officer since 2016. Prior to that, he was Prothena Corporation Plc Chief Operating Officer for part of 2016, and prior to that he was Prothena Corporation Plc Chief Scientific Officer and Head of Research and Development from 2012 to 2016. From 2009 to 2012, Dr. Kinney held various positions with Elan Pharmaceuticals, Inc.: Vice President, Pharmacology (from 2011 to 2012) and Senior Vice President of Pharmacological Sciences (from 2009 to 2011); and while in those positions, he also served as Head of Nonclinical Research for Janssen Alzheimer Immunotherapy R&D. From 2001 to 2009, Dr. Kinney was Senior Director, Head of Central Pharmacology and acting lead for Bioanalytics & Pathology at the Merck Research Laboratories, where he contributed to the strategic direction and oversight of drug discovery activities and led a number of non-clinical discovery and clinical development programs targeted for the treatment of neurodegenerative and psychiatric conditions. Dr. Kinney also held positions at Bristol Myers Squibb and was an Assistant Professor at the Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences. He earned his B.A. from Bloomsburg University and his M.A. and Ph.D. from Florida Atlantic University. Dr. Kinney has served on Prothena Corporation Plc Board since 2016.- Gene Kinney，自2016年起担任Prothena Corporation plc总裁兼首席执行官。在此之前，他在2016年部分时间担任Prothena Corporation plc首席运营官，在此之前，他在2012年至2016年期间担任Prothena Corporation plc首席科学官和研发主管。2009年至2012年，Kinney博士在Elan Pharmaceuticals，Inc.担任过多个职位：药理学副总裁（2011年至2012年）和药理科学高级副总裁（2009年至2011年）；在这些职位上，他还担任过杨森阿尔茨海默氏症免疫疗法研发的非临床研究主管。从2001年到2009年，Kinney博士在默沙东研究实验室担任高级主任、中央药理学负责人以及生物分析和病理学代理负责人，在那里他为药物发现活动的战略方向和监督做出了贡献，并领导了许多针对神经退行性和精神疾病治疗的非临床发现和临床开发项目。Kinney博士还曾在百时美施贵宝任职，曾任埃默里大学医学院精神病学和行为科学系助理教授。他在布卢姆斯堡大学获得了学士学位，在佛罗里达大西洋大学获得了硕士和博士学位。Kinney博士自2016年起在Prothena Corporation plc董事会任职。
- Gene Kinney,as served as Prothena Corporation Plc President and Chief Executive Officer since 2016. Prior to that, he was Prothena Corporation Plc Chief Operating Officer for part of 2016, and prior to that he was Prothena Corporation Plc Chief Scientific Officer and Head of Research and Development from 2012 to 2016. From 2009 to 2012, Dr. Kinney held various positions with Elan Pharmaceuticals, Inc.: Vice President, Pharmacology (from 2011 to 2012) and Senior Vice President of Pharmacological Sciences (from 2009 to 2011); and while in those positions, he also served as Head of Nonclinical Research for Janssen Alzheimer Immunotherapy R&D. From 2001 to 2009, Dr. Kinney was Senior Director, Head of Central Pharmacology and acting lead for Bioanalytics & Pathology at the Merck Research Laboratories, where he contributed to the strategic direction and oversight of drug discovery activities and led a number of non-clinical discovery and clinical development programs targeted for the treatment of neurodegenerative and psychiatric conditions. Dr. Kinney also held positions at Bristol Myers Squibb and was an Assistant Professor at the Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences. He earned his B.A. from Bloomsburg University and his M.A. and Ph.D. from Florida Atlantic University. Dr. Kinney has served on Prothena Corporation Plc Board since 2016.
- Karin L. Walker
Karin L. Walker，自2013年起担任首席会计官、财务总监。在加入Prothena之前，她是生物制药公司Affymax，Inc.的财务副总裁兼首席会计官，2012年至2013年担任该职位。2009年至2012年，Walker女士在Amyris Inc.（一家生物技术公司）担任副总裁、财务和公司财务总监。2006年至2009年，她担任CV Therapeutics，Inc.（一家生物制药公司）的副总裁、财务和公司财务总监。Walker女士还曾在Knight Ridder Digital、Accellion、Niku Corporation、Financial Engines，Inc.和NeoMagic Corporation担任高级财务领导职务。她在加州州立理工大学圣路易斯奥比斯波获得商学学士学位，是一名注册会计师。
Karin L. Walker has served as Chief Accounting Officer and Controller since 2013. Prior to joining Prothena, she was Vice President, Finance and Chief Accounting Officer of Affymax, Inc. a biopharmaceutical company, a position she held from 2012 to 2013. From 2009 to 2012 Ms. Walker was Vice President, Finance and Corporate Controller at Amyris Inc. (a biotechnology company). From 2006 to 2009 she was Vice President, Finance and Corporate Controller for CV Therapeutics, Inc. (a biopharmaceutical company). Ms. Walker also held senior financial leadership positions at Knight Ridder Digital, Accellion, Niku Corporation, Financial Engines, Inc. and NeoMagic Corporation. She earned her BS in business from the California State Polytechnic University, San Luis Obispo, and is a certified public accountant.- Karin L. Walker，自2013年起担任首席会计官、财务总监。在加入Prothena之前，她是生物制药公司Affymax，Inc.的财务副总裁兼首席会计官，2012年至2013年担任该职位。2009年至2012年，Walker女士在Amyris Inc.（一家生物技术公司）担任副总裁、财务和公司财务总监。2006年至2009年，她担任CV Therapeutics，Inc.（一家生物制药公司）的副总裁、财务和公司财务总监。Walker女士还曾在Knight Ridder Digital、Accellion、Niku Corporation、Financial Engines，Inc.和NeoMagic Corporation担任高级财务领导职务。她在加州州立理工大学圣路易斯奥比斯波获得商学学士学位，是一名注册会计师。
- Karin L. Walker has served as Chief Accounting Officer and Controller since 2013. Prior to joining Prothena, she was Vice President, Finance and Chief Accounting Officer of Affymax, Inc. a biopharmaceutical company, a position she held from 2012 to 2013. From 2009 to 2012 Ms. Walker was Vice President, Finance and Corporate Controller at Amyris Inc. (a biotechnology company). From 2006 to 2009 she was Vice President, Finance and Corporate Controller for CV Therapeutics, Inc. (a biopharmaceutical company). Ms. Walker also held senior financial leadership positions at Knight Ridder Digital, Accellion, Niku Corporation, Financial Engines, Inc. and NeoMagic Corporation. She earned her BS in business from the California State Polytechnic University, San Luis Obispo, and is a certified public accountant.